Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 9/20 | 0.47 |
| ▸ | BCHE | P06276 | 8/20 | 0.47 |
| ▸ | MBTPS1 | Q14703 | 3/20 | 0.47 |
| ▸ | F10 | P00742 | 1/20 | 0.47 |
| ▸ | PLAU | P00749 | 1/20 | 0.47 |
| ▸ | LPAR1 | Q92633 | 1/20 | 0.46 |
| ▸ | LPAR5 | Q9H1C0 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 2/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.42 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2986841 | 0.90 | BCHE (0.44) | ACHEBCHEMBTPS1F10PLAU | |
| SCHEMBL13009803 | 0.90 | BCHE (0.42) | ACHEBCHEMBTPS1F10PLAU | |
| SCHEMBL2988749 | 0.90 | PDE6D (0.45) | ACHEBCHEMBTPS1F10PLAU | |
| SCHEMBL2997165 | 0.89 | CYP4F2 (0.46) | ACHEBCHELPAR1LPAR5MEN1 | |
| SCHEMBL13009695 | 0.89 | BCHE (0.45) | ACHEBCHELPAR1LPAR5 | |
| SCHEMBL13009700 | 0.89 | BCHE (0.45) | ACHEBCHELPAR1LPAR5 | |
| SCHEMBL13009892 | 0.89 | BCHE (0.45) | ACHEBCHELPAR1LPAR5 | |
| SCHEMBL13009781 | 0.88 | MAPT (0.41) | ACHEBCHEMBTPS1F10PLAU | |
| SCHEMBL13009809 | 0.88 | MAPT (0.44) | ACHEBCHEMBTPS1F10PLAU | |
| SCHEMBL2995656 | 0.88 | LMNA (0.44) | ACHEBCHEMBTPS1F10PLAU |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100317854-A1 | NOVEL AMINODICARBOXYLIC ACID DERIVATIVES HAVING PHARMACEUTICAL PROPERTIES | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2010-12-16 | — | — | US | disclosed |
| US-20100317854-A1 | NOVEL AMINODICARBOXYLIC ACID DERIVATIVES HAVING PHARMACEUTICAL PROPERTIES | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2010-12-16 | — | — | US | disclosed |
| US-20100317854-A1 | NOVEL AMINODICARBOXYLIC ACID DERIVATIVES HAVING PHARMACEUTICAL PROPERTIES | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2010-12-16 | — | — | US | disclosed |
| US-7781470-B2 | Aminodicarboxylic acid derivatives having pharmaceutical properties | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2010-08-24 | — | — | US | disclosed |
| US-7781470-B2 | Aminodicarboxylic acid derivatives having pharmaceutical properties | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2010-08-24 | — | — | US | disclosed |
| US-7781470-B2 | Aminodicarboxylic acid derivatives having pharmaceutical properties | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2010-08-24 | — | — | US | disclosed |
| US-20090203906-A1 | NOVEL AMINODICARBOXYLIC ACID DERIVATIVES HAVING PHARMACEUTICAL PROPERTIES | BAYER AKTIENGESELLSCHAFT (DE) | 2009-08-13 | — | — | US | disclosed |
| US-20090203906-A1 | NOVEL AMINODICARBOXYLIC ACID DERIVATIVES HAVING PHARMACEUTICAL PROPERTIES | BAYER AKTIENGESELLSCHAFT (DE) | 2009-08-13 | — | — | US | disclosed |
| US-20090203906-A1 | NOVEL AMINODICARBOXYLIC ACID DERIVATIVES HAVING PHARMACEUTICAL PROPERTIES | BAYER AKTIENGESELLSCHAFT (DE) | 2009-08-13 | — | — | US | disclosed |
| US-7517896-B2 | Aminodicarboxylic acid derivatives having pharmaceutical properties | BAYER AKTIENGESELLSCHAFT (DE) | 2009-04-14 | — | — | US | disclosed |
| US-7517896-B2 | Aminodicarboxylic acid derivatives having pharmaceutical properties | BAYER AKTIENGESELLSCHAFT (DE) | 2009-04-14 | — | — | US | disclosed |
| US-7517896-B2 | Aminodicarboxylic acid derivatives having pharmaceutical properties | BAYER AKTIENGESELLSCHAFT (DE) | 2009-04-14 | — | — | US | disclosed |
| US-7087644-B1 | Derivatives of dicarboxylic acid having pharmaceutical properties | BAYER AKTIENGESELLSCHAFT (DE) | 2006-08-08 | — | — | US | disclosed |
| US-20060094769-A1 | Novel aminodicarboxylic acid derivatives having pharmaceutical properties | BAYER AKTIENGESELLSCHAFT (DE) | 2006-05-04 | — | — | US | disclosed |
| EP-1216225-B1 | NOVEL DERIVATIVES OF DICARBOXYLIC ACID HAVING PHARMACEUTICAL PROPERTIES | BAYER HEALTHCARE AG (DE) | 2005-07-06 | — | — | EP | disclosed |
| EP-1216225-A2 | NOVEL DERIVATIVES OF DICARBOXYLIC ACID HAVING PHARMACEUTICAL PROPERTIES | Bayer Aktiengesellschaft (DE) | 2002-06-26 | — | — | EP | disclosed |
| WO-2001019780-A2 | NOVEL DERIVATIVES OF DICARBOXYLIC ACID HAVING PHARMACEUTICAL PROPERTIES | BAYER AKTIENGESELLSCHAFT (DE) | 2001-03-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090203906-A1 | NOVEL AMINODICARBOXYLIC ACID DERIVATIVES HAVING PHARMACEUTICAL PROPERTIES | DDC, AADAT, PTGIS | ACHE 4159/4885BCHE 2440/4885MBTPS1 3882/4885 |
| US-20100317854-A1 | NOVEL AMINODICARBOXYLIC ACID DERIVATIVES HAVING PHARMACEUTICAL PROPERTIES | DDC, AADAT, PTGIS | ACHE 4159/4885BCHE 2440/4885MBTPS1 3882/4885 |
| US-20060094769-A1 | Novel aminodicarboxylic acid derivatives having pharmaceutical properties | DDC, AADAT, PTGIS | ACHE 4159/4885BCHE 2440/4885MBTPS1 3882/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.